RxSight (RXST) Cash from Financing Activities (2020 - 2026)

RxSight (RXST) has 7 years of Cash from Financing Activities data on file, last reported at -$336000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 54.29% year-over-year to -$336000.0; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (down 98.03% YoY), and the FY2025 full-year result was $1.9 million, down 98.49% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$336000.0, down from $1.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $111.5 million in Q2 2024 and bottomed at -$8.2 million in Q3 2023.
• The 5-year median for Cash from Financing Activities is $891000.0 (2023), against an average of $11.3 million.
• Peak annual rise in Cash from Financing Activities reached 66737.76% in 2023, while the deepest fall reached 1709.67% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $6.3 million in 2022, then slumped by 43.52% to $3.6 million in 2023, then dropped by 16.45% to $3.0 million in 2024, then plunged by 64.28% to $1.1 million in 2025, then sank by 131.61% to -$336000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$336000.0 (Q1 2026), $1.1 million (Q4 2025), and -$530000.0 (Q3 2025), per Business Quant data.

Peer Comparison